Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (2535)	4/22/2008 2:35:46 PM
From: scaram(o)uche	Read Replies (1) of 3158

>> I cannot seem to fathom a RIGL bid due to the tox seen clinically. << I'd be interested in how your view differs from that of Birchenough (and I guess that would include how your view differs from mine, as I share Birchenough's). I'll just point to his thoughts, as they include JAK3 commentary and RIGL also has a JAK3 inhibitor (R348) in development..... Message 24132675 For those following along, here's a synopsis of the troubling tox results observed in the phase II RA trial....... ir.rigel.com TIA for any additional comments. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next